ArticlePloS one2026
Protection of beta-blocker and 5-hydroxytryptamine 1A receptor agonist on myocardial ischemia injury in rats by regulating the NLRP3/Caspase-1/GSDMD pathway.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effects and related mechanisms of a β-blocker combined with a 5-hydroxytryptamine 1A receptor (5-HT1AR) agonist on MI injuries in rats.
methodsTTC/Evans blue, H&E, Masson, and TUNEL staining were used to assess infarction area, pathological damage, fibrosis, and apoptosis in myocardial tissue. The ELISA kits were used to detect IL-1β and IL-18 levels. The immunohistochemical (IHC) staining was used in conjunction with qRT-PCR and Western blot to determine IL-1β, IL-18, NLRP3, pro Caspase-1, cleaved Caspase-1, GSDMD-FL, and GSDMD-N expression levels.
resultsIn myocardial tissue, the β-blocker combined with the 5-HT1AR agonist effectively reduced infarction size, mitigated pathological injury, alleviated fibrosis, and prevented apoptosis. Meanwhile, the β-blocker combined with the 5-HT1AR agonist downregulated IL-1β and IL-18 levels in serum and myocardial tissue. Notably, although it barely altered the expression of the pyroptosis precursor proteins pro Caspase‑1 and GSDMD‑FL, the combined therapy strongly suppressed the mRNA and protein levels of NLRP3, cleaved Caspase‑1, and GSDMD‑N, and reduced the ratios of pro Caspase‑1/cleaved Caspase‑1 and GSDMD-FL/GSDMD-N in myocardial tissue.
conclusionβ-blocker combined with the 5-HT1AR agonist relieves MI injuries by suppressing the NLRP3/Caspase-1/GSDMD pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.